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Identity 
Other names: PFK/FBPase 4 




PFKFB4 is composed of 14 exons and spans 44332 bp 
on the minus strand. 
Transcription 
PFKFB4 NM_004567.2 contains 3586 bases and the 
open reading starts at 114 bases to finish at 1410 bases. 
There are nine putative splice variants that are protein 
coding, as reported in the Ensembl database. Moreover, 
several splice variants have been reported in rat tissues, 
as well as in DB-1 melanoma cells. Notably, the PFK-2 
core domain is conserved among all splice variants 
(Minchenko et al., 2005b; Minchenko et al., 2008; Ros 
and Schulze, 2013). 
Protein 
Description 
PFKFB4 consists of 469 residues and has a molecular 
weight of 54040 Da. 
PFKFB4 is one of the four isoforms (PFKFB1-
PFKFB2-PFKFB3-PFKFB4) of the bifunctional 
enzyme PFK2 (6-phosphofructo-2-kinase/fructose-2,6-
bisphosphatase), differing in their kinetic and 
regulatory properties. 
The PFK2 enzyme has both kinase and phosphatase 
activities, producing or degrading fructose-2,6-
bisphosphate (Fru-2,6-P2).  
6-Phosphofructo-2-kinase (6-PF-2-K) synthesizes Fru-
2,6-P2 from fructose-6-phosphate (F6P) and ATP, 
while fructose-2,6-bisphosphatase (Fru-2,6-P2ase) 
hydrolyzes Fru-2,6-P2 to form F6P and inorganic 
phosphate (Pi).  
 
 
Figure 1: Schematic representation of the structure of the bifunctional isozyme PFKFB4. The different potential sites were defined 
by mutagenesis or by structural similarity to other mononucleotide binding proteins and phosphoglucomutases (Hasemann et al., 1996; 
Yuen et al., 1999a; Yuen et al., 1999b; Tominaga et al., 1993; Uyeda et al., 1997). 
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Fru-2,6-P2 is a rate-limiting enzyme product and an 
important control point in glycolysis and 
gluconeogenesis via its stimulatory effect on 
phosphofructokinase 1 (PFK1) activity and its 
inhibitory effect on fructose-1,6-bisphosphatase (Fru-
1,6-P2ase) (Pilkis et al., 1996). 
The mammalian PFKFB4 gene encodes an isozyme 
originally identified as a homodimer in the testis 
(Sakata et al., 1991; Manzano et al., 1999; Gomez et 
al., 2005). 
The enzyme is divided into two functional domains 
(Figure 1): the N-terminal catalytic domain in which 
the 6-PF-2-K activity is found, and the C-terminal 
domain that houses the Fru-2,6-P2ase activity. 
Expression 
PFKFB4 is expressed in testis and at specific times 
during sperm maturation (Gomez et al., 2009). A recent 
report showed that 5α-androstan-17β-ol-3-one, 
inducing the paracrine secretion of FGF-2 by Sertoli 
cells could modulate the expression of PFKFB 
isozymes during spermatogenesis (Gomez et al., 2012).  
Moreover, it was demonstrated that hypoxia, as well as 
glucose level, strongly regulate PFKFB4 mRNA and 
protein expression levels in different cancer cell lines 
from prostate and liver (Minchenko et al., 2004; Li et 
al., 2012; Ros et al., 2012). Recent studies have showed 
the cancer-specific overexpression of PFKFB4 in 
astrocytoma (Goidts et al., 2012). 
Localisation 
PFKFB4 is found in the cytosol. 
Function 
PFKFB4 is a bifunctional isozyme harboring two 
domains that function within a homodimeric protein 
complex. It synthesizes and degrades Fru-2,6-P2 as 




The first reaction (kinase) taking place at the N-
terminal side of the protein transfers the phosphate 
from ATP to F-6-P by a sequential-ordered mechanism.  
The biphosphatase reaction, which is located in the C-
terminal domain, proceeds via a covalent 
phosphohistidine intermediate at position H257 (Figure 
1) formed upon reaction with F-2,6-P2.  
The steady state concentration of F-2,6-P2 is 
determined by the balance between these opposing 
reactions.  
The kinase:biphosphatase activity ratio is different for 
all four isoforms (Okar et al., 2001).  
Indeed, the K:B ratio of the human PFKFB4 is 
approximately of 1 while PFKFB3 harbors a  
significantly higher ratio (740:1). These differences 
mainly reside on the effect of several glycolytic 
metabolites or post-translational modifications. 
Fru-2,6-P2 is a powerful allosteric activator of 
phosphofructokinase 1 (PFK-1), the enzyme that 
controls one of the most critical steps of glycolysis (Wu 
et al., 2006).  
However, Fru-2,6-P2 not only controls the PFK-1 
reaction but also the reverse reaction in the 
gluconeogenic pathway by inhibiting fructose 1,6-
bisphosphatase (FBPase-1) (Figure 3). 
 
Figure 3: Overview of the function of PFK2. 6-
phosphofructo-2-kinase/fructose 2,6-bisphosphatases (PFK-
2/FBPase-2) regulates the production of F-2,6-P2 which controls 
the production of F-1,6-P2 by activating or inhibiting PFK1. 
Homology 
There are four PFK2 isoenzymes in mammals encoded 
by four different genes (PFKFB1-PFKFB4).  
Although the different isoforms present a high 
sequence homology of their core domain, there are 
differences in their regulatory and kinetic properties, 
probably due to the structural variations in the N- and 
C-terminal regions (Ros and Schulze, 2013). 
From protein sequence alignments, it appears that the 
bisphosphatase activity is homologous to the 
phosphoglycerate mutases (PGMs) and the acid 
phosphatase family.  
The N-terminal PFK-2 domain is homologous to 
several nucleotide binding proteins, such as the NMP 
kinase (nucleoside-monophosphate kinase) (Bazan et 
al., 1989; Hasemann et al., 1996; Okar et al., 2001). 
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Mutations 
Somatic 
18 different missense somatic mutations have been 
reported in different tumor samples, such as lung, liver, 
colon or breast cancer (Sjoeblom et al., 2006; Forbes et 
al., 2011). 
Implicated in 
Non-muscle invasive bladder cancer 
(NMIBC) 
Note 
PFKFB4 mRNA and protein expression was 
investigated in NMBIC samples. 
Prognosis 
Recurrence free survival time was significantly reduced 
in patients with elevated PFKFB4 mRNA levels, 
whereas PFKFB4 protein levels did not correlate with 
differences in time to tumor recurrence.  
The time of progression free survival was significantly 
shorter in patients with increased PFKFB4 mRNA or 
protein expression levels (Yun et al., 2012). 
Breast cancer 
Note 
PFKFB4 was showed to be highly expressed in solid 
malignant tumors of the breast compared to non-
malignant tissue (Minchenko et al., 2005a). 
In several breast cancer cell lines (BT549, MCF7, 
MDA-MB468, SKBR3, TD47), PFKFB4 expression 
was increased upon exposure to hypoxia (Minchenko et 
al., 2005a, Minchenko et al., 2005c). 
Glioma 
Note 
PFKFB4 mRNA and protein expression was showed to 
be increased in three different glioblastoma stem-like 
cell lines, but not in normal brain cells. shRNA 
mediated knockdown of PFKFB4 in glioma stem-like 
cell lines led to increased apoptosis (Goidts et al., 
2012), while no phenotypic effect could be seen in 
PFKFB4-silenced normal neural stem cells. These 
results suggested a cancer-specific function of PFKFB4 
in glioblastoma. 
Prognosis 
Glioblastoma patients with tumors with higher than 
average PFKFB4 expression showed a significantly 
shorter overall survival time, compared to patients with 
lower than average PFKFB4 expression. Furthermore, 
PFKFB4 mRNA expression correlated with glioma 
tumors grade (Goidts et al., 2012). 
Oncogenesis 
Glioblastoma stem-like cells, thought to be responsible 
for chemo- and radiotherapy resistance, are resilient 
against hypoxic conditions in the tumor 
microenvironment under which the hypoxia inducible 
factor 1α (HIF1α), a transcription factor, is triggered.  
HIF1α activates transcription of PFKFB4 leading to 
higher glycolysis and production rates of lactate and 
ATP, essential for the survival of these cells. Silencing 
of PFKFB4 was showed to decrease significantly ATP 
and lactate levels, leading to the 
phosphorylation/activation of the AMPK (adenosine 
monophosphate-activated protein kinase). 
Colon cancer 
Note 
mRNA expression of PFKFB4 was significantly 
increased in colon solid malignant tumors in 




In gastric cancer tissue, PFKFB4 mRNA expression 
was increased compared to the nonmalignant 
counterpart (Bobarykina et al., 2006). 
PFKFB4 mRNA expression was found to be low in the 
gastric cancer cell lines MKN45 and NUGC3. Protein 
expression levels differed from low to highly 
expressed, but low protein levels were increased under 
hypoxic conditions (Bobarykina et al., 2006). 
Liver cancer 
Note 
In a hepatic cancer cell line (huh-7), sulforaphane-
induced apoptosis resulted in decreased PFKFB4 
protein expression and glucose consumption. PFKFB4 
expression was increased again under hypoxic 
conditions, due to the HIF1α transcription factor being 
induced and activating PFKFB4 transcription (Jeon et 
al., 2011).  
Moreover, PFKFB4 expression was suggested to be 
controlled by HO-2 (Heme oxygenase 2) in the hepatic 
cancer cell line HepG2 (Li et al., 2012). 
Pancreatic cancer 
Note 
Low levels of PFKFB4 mRNA and protein expression 
were found in the pancreatic cancer cell line Pank1, but 
expression was induced on both levels under hypoxia 
(Bobarykina et al., 2006). 
Prostate cancer 
Note 
In 3 different prostate cancer cell lines (DU145, 
LNCaP, PC3), PFKFB4 expression was higher than in 
the noncancer cell line RWPE1 (Ros et al., 2012). 
Silencing of PFKFB4 in xenografted prostate cancer 
tumors in vivo (60% reduction in PFKFB4 mRNA 
levels) resulted in significant reduction of the tumor 
size and an increased number of cells with apoptotic 
morphology. Tumor growth was positively correlated 
to PFKFB4 mRNA expression (Ros et al., 2012). 
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Oncogenesis 
PFKFB4 was accumulated upon siRNA mediated 
silencing of PFKFB4 in prostate cancer cell lines, 
leading to reduced cell survival. These findings suggest 
an enhanced phosphatase activity in prostate cancer 
cells, important for their survival. Additionally, 
depletion of PFKFB4 decreased the concentration of 
NADPH, a pentose phosphate pathway metabolite 
required for de novo synthesis of fatty acids and the 
maintenance of the antioxidant GSH, leading to 
increased levels of reactive oxygen species (Ros et al., 
2012). 
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